Azacitidine in the treatment of extramedullary relapse of AML after allogeneic hematopoietic cell transplantation

@article{Antar2013AzacitidineIT,
  title={Azacitidine in the treatment of extramedullary relapse of AML after allogeneic hematopoietic cell transplantation},
  author={Ahmad I Antar and Zaher K. Otrock and Mohamed A Kharfan-Dabaja and Ziad Salem and S{\'e}lim Aractingi and Mohamad Mohty and Ali Bazarbachi},
  journal={Bone Marrow Transplantation},
  year={2013},
  volume={48},
  pages={994-995}
}
Extramedullary relapse of AML after allogeneic hematopoietic SCT (HSCT) is rare and less well-defined than systemic disease relapse. In a European Group for Blood and Marrow Transplantation (EBMT) study, the incidence of extramedullary relapse after HSCT was as low as 0.65% in AML. However, other studies have reported an incidence of up to 20% among long-term survivors. There are no established guidelines for clinical decision making pertaining to the treatment of extramedullary relapse after… CONTINUE READING